U.S. markets open in 4 hours 11 minutes
  • S&P Futures

    3,860.25
    +41.00 (+1.07%)
     
  • Dow Futures

    31,989.00
    +213.00 (+0.67%)
     
  • Nasdaq Futures

    12,550.75
    +253.50 (+2.06%)
     
  • Russell 2000 Futures

    2,238.10
    +37.30 (+1.69%)
     
  • Crude Oil

    65.74
    +0.69 (+1.06%)
     
  • Gold

    1,700.50
    +22.50 (+1.34%)
     
  • Silver

    25.78
    +0.51 (+2.02%)
     
  • EUR/USD

    1.1908
    +0.0055 (+0.46%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.46
    -0.20 (-0.81%)
     
  • GBP/USD

    1.3876
    +0.0054 (+0.39%)
     
  • JPY=X

    108.7490
    -0.1520 (-0.14%)
     
  • BTC-USD

    54,279.09
    +4,414.43 (+8.85%)
     
  • CMC Crypto 200

    1,095.78
    +71.57 (+6.99%)
     
  • FTSE 100

    6,753.32
    +34.19 (+0.51%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

P/E Ratio Insights for Ligand Pharmaceuticals

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Looking into the current session, Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is trading at $114.70, after a 3.34% decrease. Over the past month, the stock fell by 3.95%, but over the past year, it actually spiked by 22.54%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 10.25%.

The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company’s current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.

View more earnings on LGND

Depending on the particular phase of a business cycle, some industries will perform better than others.

Ligand Pharmaceuticals Inc. has a better P/E ratio of 312.26 than the aggregate P/E ratio of 0.01 of the Biotechnology industry. Ideally, one might believe that Ligand Pharmaceuticals Inc. might perform better in the future than it’s industry group, but it’s probable that the stock is overvalued.

Price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.